BEKINDA

April 21, 2017

RedHill Wins Two More U.S. Patents on Gastrointestinal Therapy BEKINDA

News

RedHill Biopharma has received two more U.S. patents for its gastrointestinal therapy BEKINDA (ondansetron). The patents cover RedHill’s propriety formulation of its extended-release ondansetron tablet, and the way BEKINDA is ... Read more

February 14, 2017

RedHill Enrolls Last Patient in Bekinda Phase 3 Trial for Acute Gastroenteritis

News

RedHill Biopharma has enrolled the last patient in a Phase 3 clinical evaluating Bekinda (24 mg) for the treatment of acute gastroenteritis and gastritis. The drug, targeting multiple gastrointestinal indications, is also ... Read more

June 4, 2015September 28, 2016

RedHill Releases Update on Promising IBD Therapies

IBD News, News

Israel-based biopharmaceutical company RedHill Biopharma recently released an update on the development of its drug pipeline, including a treatment for Crohn’s disease, and announced key milestones expected by the company for the upcoming period. RedHill ... Read more